ProShare Advisors
ANAC

ProShare Advisors’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

ProShare Advisors’s Portfolio ANAC Stock Details ANAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-39,175
Closed -$2.09M – 1666
2016
Q1 		$2.09M Sell
39,175
-3,926
-9% -$290K 0.03% 441
2015
Q4 		$4.87M Buy
43,101
+4,020
+10% +$443K 0.06% 293
2015
Q3 		$4.6M Sell
39,081
-1,049
-3% -$137K 0.06% 286
2015
Q2 		$3.11M Sell
40,130
-795
-2% -$52.1K 0.04% 383
2015
Q1 		$2.37M Buy
40,925
+5,533
+16% +$235K 0.03% 514
2014
Q4 		$1.14M Buy
35,392
+767
+2% +$23K 0.01% 790
2014
Q3 		$847K Sell
34,625
-6,749
-16% -$137K 0.01% 1130
2014
Q2 		$734K Sell
41,374
-15,476
-27% -$249K 0.01% 1334
2014
Q1 		$1.14M Buy
56,850
+37,091
+188% +$719K 0.01% 1193
2013
Q4 		$332K Sell
19,759
-10,512
-35% -$145K ﹤0.01% 1130
2013
Q3 		$321K Buy
30,271
+10,559
+54% +$92.4K 0.01% 1859
2013
Q2 		$110K Buy
+19,712
New +$119K ﹤0.01% 2226

Other funds holding ANAC

KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return

ProShare Advisors's ANAC Position: Q2 2016 in Review

ProShare Advisors sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q2 2016, closing a stake of 39,175 shares — an estimated $2.09M sold.

ProShare Advisors first reported a position in ANAC in Q2 2013 and held it in 12 quarters. The position peaked at $4.87M in Q4 2015. 2 funds tracked by Wall St. Rank hold ANAC as of Q2 2016.

  • ProShare Advisors reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
  • ProShare Advisors sold 39,175 ANACOR PHARMACEUTICALS INC COM shares in Q2 2016, an estimated $2.09M.
  • ProShare Advisors first reported a position in ANACOR PHARMACEUTICALS INC COM in Q2 2013 and held it in 12 quarters.
  • ProShare Advisors's ANACOR PHARMACEUTICALS INC COM position peaked at $4.87M in Q4 2015.
  • 2 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q2 2016.

Based on ProShare Advisors's 13F filing for Q2 2016, filed 12 Aug 2016.